{"content":"<li class=\"n-box-item date-title\" data-end=\"1507694399\" data-start=\"1507608000\" data-txt=\"Monday, December 23, 2019\">Tuesday, October 10, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3300312\" data-ts=\"1507677844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMI\" target=\"_blank\">FMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300312-foundation-medicine-taps-civik-chief-commercial-officer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foundation Medicine taps Civik as chief commercial officer</a></h4><ul>   <li>Foundation Medicine (<a href=\"http://seekingalpha.com/symbol/FMI\" target=\"_blank\">FMI</a> <font color='red'>-3.9%</font>) has named Tom Civik its <a href=\"https://seekingalpha.com/pr/16964849-foundation-medicine-appoints-tom-civik-chief-commercial-officer\" target=\"_blank\">chief commercial officer</a>.</li>    <li>The move is effective mid-November.</li>    <li>He had previously served as a VP and officer for Genentech, where he was responsible for commercialization for several oncology products delivering more than $3B in revenue. Before that he spent eight years with Sanofi.</li>    <li>At Foundation Medicine, he'll oversee commercial and reimbursement strategies to support its clinical molecular information solutions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300312\" data-linked=\"Foundation Medicine taps Civik as chief commercial officer\" data-tweet=\"$FMI - Foundation Medicine taps Civik as chief commercial officer https://seekingalpha.com/news/3300312-foundation-medicine-taps-civik-chief-commercial-officer?source=tweet\" data-url=\"https://seekingalpha.com/news/3300312-foundation-medicine-taps-civik-chief-commercial-officer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300306\" data-ts=\"1507673242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HDSN\" target=\"_blank\">HDSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300306-hudson-technologiesminus-9_5-after-issuing-below-consensus-q3-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hudson Technologies -9.5% after issuing below consensus Q3 guidance</a></h4><ul>     <li>Hudson Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/HDSN' title='Hudson Technologies, Inc.'>HDSN</a>) <font color='red'>-9.5%</font> after-hours as it issues <a href=\"https://seekingalpha.com/pr/16964888-hudson-technologies-announces-preliminary-third-quarter-nine-month-2017-results\" target=\"_blank\">downside Q3 guidance</a>, seeing EPS of $0.03-$0.05 vs. $0.09 analyst consensus estimate on revenues of ~$25M vs. $41M consensus.</li>     <li>HDSN says the declines it had expected in price and volume for all refrigerants has been greater than anticipated, but it still expects to hit its gross margin target of 30% for the entire nine-month 2017 cooling season.</li>     <li>Separately, HDSN says it <a href=\"https://seekingalpha.com/pr/16964884-hudson-technologies-announces-closing-acquisition-airgas-refrigerants-inc\" target=\"_blank\">closed</a> its previously announced acquisition of Airgas-Refrigerants Inc.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300306\" data-linked=\"Hudson Technologies -9.5% after issuing below consensus Q3 guidance\" data-tweet=\"$HDSN - Hudson Technologies -9.5% after issuing below consensus Q3 guidance https://seekingalpha.com/news/3300306-hudson-technologiesminus-9_5-after-issuing-below-consensus-q3-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3300306-hudson-technologiesminus-9_5-after-issuing-below-consensus-q3-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300302\" data-ts=\"1507671485\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300302-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/CX' title='Cemex, S.A.B. de C.V.'>CX</a> <font color='green'>+2.0%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+1.5%</font>. <a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a> <font color='green'>+1.3%</font>. <a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a> <font color='green'>+1.4%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a> <font color='red'>-6.5%</font>. <a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a> <font color='red'>-5.8%</font>. <a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='red'>-4.4%</font>. <a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a> <font color='red'>-3.3%</font>. <a href='https://seekingalpha.com/symbol/KALV' title='KalVista Pharmaceticals, Inc.'>KALV</a> <font color='red'>-1.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300302\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ALT $CX $MNKD - After Hours Gainers / Losers https://seekingalpha.com/news/3300302-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3300302-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300280\" data-ts=\"1507668135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDP\" target=\"_blank\">MDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300280-time-launches-print-cutbacks-newsweekly-si-fortune-and-others\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Time launches print cutbacks at newsweekly, SI, Fortune and others</a></h4><ul>   <li>Time Inc. (<a href=\"http://seekingalpha.com/symbol/TIME\" target=\"_blank\">TIME</a> <font color='green'>+2%</font>) is <a href=\"https://www.wsj.com/articles/for-time-inc-s-magazines-fewer-copies-is-the-way-forward-1507667214?mod=e2tw\" target=\"_blank\">cutting back on its print</a> -- both in circulation and in frequency of key magazine titles -- as it works to preserve profit at its longstanding brands.</li>    <li>It intends to cut circulation of weekly <i>Time</i> magazine by a third, to 2M copies, in part by cutting back on promotional copies and focusing more on an ad-friendly core audience. It will cut circulation for <i>People en Espanol</i> as well.</li>    <li>Meanwhile, seven other titles will come out less often, including <i>Sports Illustrated, Entertainment Weekly</i> and <i>Fortune.</i> In 2018, <i>SI</i> will publish 27 issues rather than this year's 38, but there will be 23% more editorial pages in each, on a weightier paper stock.</li>    <li>The moves are effective Jan. 1.</li>    <li>A revenue hit is expected, as the company will likely lower ad rates to make up for reduced circulation, but the bet is that expense savings will be bigger.</li>    <li>After hours: TIME <font color='red'>-0.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300280\" data-linked=\"Time launches print cutbacks at newsweekly, SI, Fortune and others\" data-tweet=\"$MDP - Time launches print cutbacks at newsweekly, SI, Fortune and others https://seekingalpha.com/news/3300280-time-launches-print-cutbacks-newsweekly-si-fortune-and-others?source=tweet\" data-url=\"https://seekingalpha.com/news/3300280-time-launches-print-cutbacks-newsweekly-si-fortune-and-others\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300273\" data-ts=\"1507667351\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300273-micron-announces-1b-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron announces $1B stock offering</a></h4><ul><li>        Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) <a href=\"https://seekingalpha.com/pr/16964743-micron-launches-1-billion-offering-common-stock\" target=\"_blank\">announces</a> a $1B common stock offering.</li><li>               The underwriter, J.P. Morgan, has a 30-day option to purchase up to $150M in additional shares.&nbsp;</li><li>               Micron will use $476M of the net proceeds to redeem $438M of its 7.5% Senior Secured Notes due 2023. The rest will go towards future repurchases and debt repayments.&nbsp;</li><li>               Micron shares are&nbsp;<font color='red'>down 3.05%</font>&nbsp;aftermarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300273\" data-linked=\"Micron announces $1B stock offering\" data-tweet=\"$MU - Micron announces $1B stock offering https://seekingalpha.com/news/3300273-micron-announces-1b-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3300273-micron-announces-1b-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>393&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300271\" data-ts=\"1507667206\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANAB\" target=\"_blank\">ANAB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300271-anaptysbio-readies-3m-share-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AnaptysBio readies 3M-share stock offering</a></h4><ul><li>AnaptysBio (NASDAQ:<a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio'>ANAB</a>) files an <a href=\"https://www.sec.gov/Archives/edgar/data/1370053/000119312517307069/d453477ds1.htm\" target=\"_blank\">S-1</a> to register a 3M-share public offering of common stock. Net proceeds are projected to be ~$98.6M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300271\" data-linked=\"AnaptysBio readies 3M-share stock offering\" data-tweet=\"$ANAB - AnaptysBio readies 3M-share stock offering https://seekingalpha.com/news/3300271-anaptysbio-readies-3m-share-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3300271-anaptysbio-readies-3m-share-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300268\" data-ts=\"1507666654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUDA\" target=\"_blank\">CUDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300268-barracuda-networksminus-6_9-after-in-line-q2-profits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barracuda Networks -6.9% after in-line Q2 profits</a></h4><ul>   <li>Barracuda Networks (NYSE:<a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a>) has <font color='red'>slipped 6.9%</font> after hours following <a href=\"https://seekingalpha.com/news/3300256-barracuda-networks-eps-line-beats-revenue\" target=\"_blank\">Q2 earnings</a> where gross profit grew, but increased sales/marketing expenses cut into net profits.</li>    <li>EPS was in line with expectations, and revenues rose just over 7%.</li>    <li>Gross billings were $108.5M vs. a year-ago $100.3M; billings for core products were up 22% to $70.9M.</li>    <li>Revenue breakout: Appliance, $18.35M (down 12.8%); Subscription, $75.98M (up 13.6%).</li>    <li>Active subscribers rose 17%, to more than 348,000. Annualized renewal rate on a dollar basis was 91%.</li>    <li><a href=\"https://investors.barracuda.com/\" target=\"_blank\">Conference call</a> to come at 4:30 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16964701-barracuda-reports-second-quarter-fiscal-2018-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3300268\" data-linked=\"Barracuda Networks -6.9% after in-line Q2 profits\" data-tweet=\"$CUDA - Barracuda Networks -6.9% after in-line Q2 profits https://seekingalpha.com/news/3300268-barracuda-networksminus-6_9-after-in-line-q2-profits?source=tweet\" data-url=\"https://seekingalpha.com/news/3300268-barracuda-networksminus-6_9-after-in-line-q2-profits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300259\" data-ts=\"1507666194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLXN\" target=\"_blank\">FLXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300259-flexion-therapeutics-readies-4m-share-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flexion Therapeutics readies 4M-share equity offering</a></h4><ul><li>Flexion Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a>) <a href=\"https://seekingalpha.com/pr/16964718-flexion-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a public offering of 4M shares of common stock. Price and terms have yet to be announced. Net proceeds will fund the manufacturing and commercialization of Zilretta.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300259\" data-linked=\"Flexion Therapeutics readies 4M-share equity offering\" data-tweet=\"$FLXN - Flexion Therapeutics readies 4M-share equity offering https://seekingalpha.com/news/3300259-flexion-therapeutics-readies-4m-share-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3300259-flexion-therapeutics-readies-4m-share-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300251\" data-ts=\"1507664952\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DO\" target=\"_blank\">DO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300251-diamond-offshore-on-move-fbr-takes-down-sell-rating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diamond Offshore on the move as FBR takes down Sell rating</a></h4><ul>     <li>Diamond Offshore (<a href='https://seekingalpha.com/symbol/DO' title='Diamond Offshore Drilling Inc.'>DO</a> <font color='green'>+1.9%</font>) is higher after FBR <a href=\"http://www.barrons.com/articles/diamond-offshore-still-too-rough-for-a-buy-1507657026\" target=\"_blank\">upgrades</a> shares to Neutral from Sell with a $13 price target, saying at least 15-20 of the preservation or warm-stacked units will be reactivated in the near-term.</li><li>When it comes to the rest of the existing unmarketed rigs, FBR believes those that end up scrapped will be retired  at a slower clip than the industry has seen to date.</li><li>Finally, the firm notes its demand view supports a higher fleet net asset value, but on the supply side it sees any further upside restricted by the industry's excess  capacity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300251\" data-linked=\"Diamond Offshore on the move as FBR takes down Sell rating\" data-tweet=\"$DO - Diamond Offshore on the move as FBR takes down Sell rating https://seekingalpha.com/news/3300251-diamond-offshore-on-move-fbr-takes-down-sell-rating?source=tweet\" data-url=\"https://seekingalpha.com/news/3300251-diamond-offshore-on-move-fbr-takes-down-sell-rating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300246\" data-ts=\"1507664160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSTK\" target=\"_blank\">OSTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300246-overstock-comminus-8-after-hitting-52-week-high-earlier\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Overstock.com -8% after hitting 52-week high earlier</a></h4><ul> <li>Volume on Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>) is sky high on a day the stock broke to a 52-week high of $33.30.</li> <li>Shares hit the mark around noon before investors pulled out the rug. Overstock.com is&nbsp;<font color='red'>down 7.42%</font>&nbsp;at last check on the day on volume of 4.40M shares vs. 707K average daily volume.</li> <li>There's some reports on Twitter indicating the Overstock.com was mentioned favorably at Grant's Fall 2017 conference.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300246\" data-linked=\"Overstock.com -8% after hitting 52-week high earlier\" data-tweet=\"$OSTK - Overstock.com -8% after hitting 52-week high earlier https://seekingalpha.com/news/3300246-overstock-comminus-8-after-hitting-52-week-high-earlier?source=tweet\" data-url=\"https://seekingalpha.com/news/3300246-overstock-comminus-8-after-hitting-52-week-high-earlier\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300243\" data-ts=\"1507663169\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVHY\" target=\"_blank\">VIVHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300243-reports-vivendi-offering-payment-to-settle-mediaset-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reports: Vivendi offering payment to settle Mediaset dispute</a></h4><ul>   <li>With tensions still high over a pay TV deal gone awry, Vivendi (<a href=\"http://seekingalpha.com/symbol/VIVHY\" target=\"_blank\">VIVHY</a> <font color='green'>+1.3%</font>) is <a href=\"https://www.reuters.com/article/us-mediaset-vivendi/vivendi-offers-compensation-to-settle-dispute-with-mediaset-sources-idUSKBN1CF2AV\" target=\"_blank\">offering to pay Mediaset</a> (<a href=\"http://seekingalpha.com/symbol/MDIUY\" target=\"_blank\">MDIUY</a> <font color='green'>+14.1%</font>) to settle a legal dispute over the transaction, Reuters reports.</li>    <li>Vivendi had reversed course on an &euro;800M plan to buy the unit, Mediaset Premium, saying the unit had an unrealistic business plan.</li>    <li>One source tells the news service that a first-tranche payment from Vivendi of &euro;250M is imminent; another says that Mediaset could join a joint venture between Vivendi's Canal Plus and Telecom Italia (<a href=\"http://seekingalpha.com/symbol/TI\" target=\"_blank\">TI</a> <font color='red'>-0.7%</font>).</li>    <li>Mediaset and top investor Fininvest have asked for damages of more than &euro;3B, while an eventual settlement might come closer to &euro;1B, according to Bloomberg.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299967-lawyers-vivendi-mediaset-seek-resolution-thorny-dispute\" target=\"_blank\">Lawyers for Vivendi, Mediaset seek resolution of thorny dispute</a> (Oct. 09 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299542-vivendi-says-police-searching-hq-mediaset-inquiry\" target=\"_blank\">Vivendi says police searching HQ in Mediaset inquiry</a> (Oct. 05 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300243\" data-linked=\"Reports: Vivendi offering payment to settle Mediaset dispute\" data-tweet=\"$VIVHY $VIVHY $MDIUY - Reports: Vivendi offering payment to settle Mediaset dispute https://seekingalpha.com/news/3300243-reports-vivendi-offering-payment-to-settle-mediaset-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3300243-reports-vivendi-offering-payment-to-settle-mediaset-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300242\" data-ts=\"1507662651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300242-nvidia-partners-announce-self-driving-delivery-truck-test-fleet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia, partners announce self-driving delivery truck test fleet</a></h4><ul><li>        Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) <a href=\"https://nvidianews.nvidia.com/news/deutsche-post-dhl-group-selects-nvidia-drive-px-for-autonomous-delivery-truck-fleet\" target=\"_blank\">announces</a> partnerships with logistics company Deutsche Post DHL Group &#40;DPDHL&#41; and automotive supplier ZF to deploy a test fleet of self-driving delivery trucks starting next year.</li><li>               DPDHL will outfit its fleet of 3.4K electric light trucks with ZF&rsquo;s ProAI self-driving system, which was developed using Nvidia&rsquo;s DRIVE PX technology.&nbsp;</li><li>Nvidia shares are&nbsp;<font color='green'>up 2.3%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300075-nvidia-unveils-new-self-driving-taxi-hardware\" target=\"_blank\">Nvidia unveils new self-driving taxi hardware</a> (Oct. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300242\" data-linked=\"Nvidia, partners announce self-driving delivery truck test fleet\" data-tweet=\"$NVDA - Nvidia, partners announce self-driving delivery truck test fleet https://seekingalpha.com/news/3300242-nvidia-partners-announce-self-driving-delivery-truck-test-fleet?source=tweet\" data-url=\"https://seekingalpha.com/news/3300242-nvidia-partners-announce-self-driving-delivery-truck-test-fleet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300237\" data-ts=\"1507661499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300237-technology-top-gainers-losers-of-2-50-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:50 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+29%</font>. WPCS <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300237\" data-linked=\"Technology - Top Gainers / Losers as of 2:50 pm\" data-tweet=\"$HMNY $DCAR $SCON - Technology - Top Gainers / Losers as of 2:50 pm https://seekingalpha.com/news/3300237-technology-top-gainers-losers-of-2-50-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300237-technology-top-gainers-losers-of-2-50-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300236\" data-ts=\"1507661351\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EWP\" target=\"_blank\">EWP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300236-catalan-president-declares-deferred-independence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalan president declares &#39;deferred independence&#39;</a></h4><ul><li>Catalan President&nbsp;Carles Puigdemont defuses at least a little bit of tension with Madrid, <a href=\"https://www.nytimes.com/2017/10/10/world/europe/spain-catalonia-independence-carles-puigdemont.html?_r=0\" target=\"_blank\">declaring independence, but then stopping</a> the separation process to instead have talks with the Spanish government.</li><li>Puigdemont and his team remain in danger of arrest for sedition, and Spanish President Mariano Rajoy has previously rejected any talks until secession plans are abandoned.</li><li>A Rajoy spokesman following&nbsp;Puigdemont's speech: \"He has made a deferred declaration of independence ... [Puigdemont]&nbsp;has taken his irresponsibility to the absolute extreme by ignoring the laws, citizens.\"</li><li>Down earlier in the session, the Spanish ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/EWP' title='iShares MSCI Spain Capped ETF'>EWP</a>) has jumped into the green, now&nbsp;<font color='green'>up 1.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300236\" data-linked=\"Catalan president declares &#39;deferred independence&#39;\" data-tweet=\"$EWP - Catalan president declares &#39;deferred independence&#39; https://seekingalpha.com/news/3300236-catalan-president-declares-deferred-independence?source=tweet\" data-url=\"https://seekingalpha.com/news/3300236-catalan-president-declares-deferred-independence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300235\" data-ts=\"1507661136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFTBY\" target=\"_blank\">SFTBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300235-bearish-on-merger-talk-deutsche-bank-trims-sprint-t-mobile-targets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bearish on merger talk, Deutsche Bank trims Sprint, T-Mobile targets</a></h4><ul>   <li>Deutsche Bank has trimmed price targets on Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color='red'>-2.9%</font>) and T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color='red'>-0.5%</font>), saying the much-discussed merger talks face risks as the coming election year brings a swell of populism.</li>    <li>\"We remain <a href=\"http://www.investors.com/news/technology/sprint-swoons-amid-worries-politics-could-hinder-t-mobile-deal/\" target=\"_blank\">very bearish on the prospects for deal approval</a>,\" analyst Matthew Niknam says, trimming the firm's target on Sprint to $7 from $8 (Sprint's down to $7.09 today), and on T-Mobile to $65 from $70 (implying 6.1% upside).</li>    <li>A less corporate-friendly mood is taking over, he notes: \"The Democrats' Better Deal agenda highlights ongoing corporate consolidation as a threat to U.S. consumers, and proposes sharper scrutiny of potential deals.\"</li>    <li>Also today: Sprint owner SoftBank (<a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a>) <font color='green'>up 2.8%</font>; T-Mobile parent Deutsche Telekom (<a href='https://seekingalpha.com/symbol/DTEGY' title='Deutsche Telekom AG ADR'>OTCQX:DTEGY</a>) <font color='green'>up 0.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300235\" data-linked=\"Bearish on merger talk, Deutsche Bank trims Sprint, T-Mobile targets\" data-tweet=\"$SFTBY $SFTBY $DTEGY - Bearish on merger talk, Deutsche Bank trims Sprint, T-Mobile targets https://seekingalpha.com/news/3300235-bearish-on-merger-talk-deutsche-bank-trims-sprint-t-mobile-targets?source=tweet\" data-url=\"https://seekingalpha.com/news/3300235-bearish-on-merger-talk-deutsche-bank-trims-sprint-t-mobile-targets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>121&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300228\" data-ts=\"1507658947\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSY\" target=\"_blank\">INSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300228-insys-continues-slide-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insys continues slide, down 9%</a></h4><ul><li>Insys Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='red'>-9.4%</font>) is down again, this time on almost double normal volume. Shares have retreated nearly 24% since touching $10.31 on October 3.</li><li>Not helping matters is an updated CDC <a href=\"https://www.cdc.gov/nchs/products/vsrr/drug-overdose-data.htm\" target=\"_blank\">report </a>that shows U.S. drug overdose deaths were up 20% in February 2017.</li><li>The company is in the midst of a flurry of lawsuits over its alleged misconduct in marketing Subsys (fentanyl).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299588-new-jersey-ag-jumps-insys-suing-bandwagon-four-court-lawsuit\" target=\"_blank\">New Jersey AG jumps on the Insys-suing bandwagon with four-court lawsuit</a> (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300228\" data-linked=\"Insys continues slide, down 9%\" data-tweet=\"$INSY $INSYQ - Insys continues slide, down 9% https://seekingalpha.com/news/3300228-insys-continues-slide-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3300228-insys-continues-slide-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300227\" data-ts=\"1507658547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300227-credit-suisse-on-national-beverage-corp\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse on National Beverage Corp.</a></h4><ul> <li>Credit Suisse updates on National Beverage Corp. (<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='green'>+1%</font>)&nbsp;after taking in the company's annual shareholders meeting last week. A few key pullouts from analyst Laurent Grandent's note.</li> <li>\"CEO Caporella is clearly passionate about the brand he is building. He theatrically reminded investors that his goal is to do more than just sell sparkling water, but it's to build a cult brand appealing to the 83M millennia consumers.\"</li> <li>\"The company detailed a number of ways it plans to drive growth of LaCroix. These include multiple flavor innovations, multipacks for the Club channel (including Curate), and the recent launch in Canada.\"</li> <li>\"We think the probability of FIZZ being acquired has been reduced even further due to the excessive trading value of the shares, in our view, but also because the most likely acquirers either have their hands full with recent acquisitions (NYSE:<a href='https://seekingalpha.com/symbol/DPS-OLD' title='Dr Pepper Snapple Group, Inc.'>DPS-OLD</a>) or are currently in the process of building their own sparkling / flavored sparkling brands (KO and PEP).\"</li> <li>CS saw enough at the meeting to take its EPS&nbsp;estimates on FIZZ&nbsp;for FY17 through FY19 slightly higher.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300227\" data-linked=\"Credit Suisse on National Beverage Corp.\" data-tweet=\"$FIZZ $FIZZ $DPS-OLD - Credit Suisse on National Beverage Corp. https://seekingalpha.com/news/3300227-credit-suisse-on-national-beverage-corp?source=tweet\" data-url=\"https://seekingalpha.com/news/3300227-credit-suisse-on-national-beverage-corp\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300225\" data-ts=\"1507658438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300225-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CHNR' title='China Natural Resources, Inc.'>CHNR</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/ESTE' title='Earthstone Energy, Inc.'>ESTE</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services'>TUSK</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/TELL' title='Tellurian Inc.'>TELL</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/HLX' title='Helix Energy Solutions Group, Inc.'>HLX</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/APA' title='Apache Corporation'>APA</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300225\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$CHNR $ESTE $TUSK - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3300225-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300225-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300222\" data-ts=\"1507657196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORT\" target=\"_blank\">CORT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300222-corcept-rebounds-from-korlym-script-data-stoked-selloff-still-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corcept rebounds from Korlym script data-stoked selloff, but still down 8%</a></h4><ul><li>Corcept Therapeutics (<a href='https://seekingalpha.com/symbol/CORT' title='Corcept Therapeutics Incorporated'>CORT</a> <font color='red'>-7.5%</font>) was down almost&nbsp;<font color='red'>20%</font>&nbsp;earlier in the session before bouncing back. Volume is over 2.5x normal.</li><li>The selloff was triggered by an alleged <a href=\"https://www.streetinsider.com/Analyst+Comments/Corcept+Therapeutics+%28CORT%29+Selling+Off+in+Misunderstanding+-+Stifel/13376594.html\" target=\"_blank\">misunderstanding </a>over prescription data on Cushing's syndrome med Korlym (mifepristone).</li><li>Stifel's Adam Walsh has spoken to management and reiterates his BUY rating and $20 price target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300222\" data-linked=\"Corcept rebounds from Korlym script data-stoked selloff, but still down 8%\" data-tweet=\"$CORT - Corcept rebounds from Korlym script data-stoked selloff, but still down 8% https://seekingalpha.com/news/3300222-corcept-rebounds-from-korlym-script-data-stoked-selloff-still-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3300222-corcept-rebounds-from-korlym-script-data-stoked-selloff-still-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300216\" data-ts=\"1507655725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBSV\" target=\"_blank\">OBSV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300216-obseva-secures-60m-private-capital-raise-shares-up-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ObsEva secures $60M private capital raise; shares up 11%</a></h4><ul><li>Thinly traded micro cap ObsEva SA (<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva'>OBSV</a> <font color='green'>+11.1%</font>) builds on its up move on average volume. Shares have rallied over&nbsp;<font color='green'>56%</font>&nbsp;this month.</li><li>Earlier today, the company <a href=\"https://seekingalpha.com/pr/16963714-obseva-sa-announces-60_0-million-private-placement-existing-new-investors\" target=\"_blank\">announced </a>that it inked an agreement with institutional investors for the direct placement of stock and warrants valued at $60M. The shares were sold at $8 which included 30-day prepaid warrants exercisable at $8.</li><li>Net proceeds will fund R&amp;D, working capital and general corporate purposes. Closing date is October 13.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300216\" data-linked=\"ObsEva secures $60M private capital raise; shares up 11%\" data-tweet=\"$OBSV - ObsEva secures $60M private capital raise; shares up 11% https://seekingalpha.com/news/3300216-obseva-secures-60m-private-capital-raise-shares-up-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3300216-obseva-secures-60m-private-capital-raise-shares-up-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300217\" data-ts=\"1507655668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MUX\" target=\"_blank\">MUX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300217-mcewen-mining-grabs-key-permit-for-gold-bar-project-in-nevada\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McEwen Mining grabs key permit for Gold Bar project in Nevada</a></h4><ul>     <li>McEwen Mining (<a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a> <font color='red'>-2.1%</font>) obtains a <a href=\"http://www.mining.com/key-permit-granted-mcewens-gold-bar-project-nevada/\" target=\"_blank\">key win in the permitting process</a> for its&nbsp;Gold Bar project&nbsp;in&nbsp;Nevada, as the EPA publishes a &ldquo;notice of availability of the final environmental impact statement.\"</li>     <li>MUX says the permit means the required National Environmental Policy Act process could be completed by November, following a review period.</li><li>Once built, the Gold Bar open-pit mine is expected to generate 65K oz./year of gold over an eight-year mine life, with production  starting in 2019.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300217\" data-linked=\"McEwen Mining grabs key permit for Gold Bar project in Nevada\" data-tweet=\"$MUX - McEwen Mining grabs key permit for Gold Bar project in Nevada https://seekingalpha.com/news/3300217-mcewen-mining-grabs-key-permit-for-gold-bar-project-in-nevada?source=tweet\" data-url=\"https://seekingalpha.com/news/3300217-mcewen-mining-grabs-key-permit-for-gold-bar-project-in-nevada\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300211\" data-ts=\"1507654812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300211-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300211\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$NOAH $PMTS - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3300211-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300211-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300210\" data-ts=\"1507654310\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300210-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio'>ANAB</a> <font color='green'>+89%</font>. <a href='https://seekingalpha.com/symbol/KALV' title='KalVista Pharmaceticals, Inc.'>KALV</a> <font color='green'>+49%</font>. <a href='https://seekingalpha.com/symbol/LINU-OLD' title='LiNiu Technology Group'>LINU-OLD</a> <font color='green'>+41%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color='green'>+24%</font>. PBMD <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> CLNT <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/BSPM' title='Biostar Pharmaceutic'>OTC:BSPM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/CORT' title='Corcept Therapeutics Incorporated'>CORT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300210\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ANAB $KALV $LINU-OLD - Midday Gainers / Losers https://seekingalpha.com/news/3300210-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3300210-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300208\" data-ts=\"1507654260\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNN\" target=\"_blank\">SNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300208-smith-nephew-up-8-on-report-of-elliott-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Smith &amp; Nephew up more than 8% on report of Elliott stake</a></h4><ul><li>According to <a href=\"https://www.bloomberg.com/news/articles/2017-10-10/singer-s-elliott-is-said-to-build-a-stake-in-smith-nephew-j8luieyf\" target=\"_blank\">Bloomberg's </a>Ed Hammond, Paul Singer's Elliott Management has built a stake in Smith &amp; Nephew (<a href='https://seekingalpha.com/symbol/SNN' title='Smith & Nephew plc'>SNN</a> <font color='green'>+8.5%</font>).</li><li>The <a href=\"http://www.smith-nephew.com/about-us/\" target=\"_blank\">company </a>develops surgical devices and wound care products. It segments its business into three areas: Sports Medicine, Trauma &amp; Other, Reconstruction and Advanced Wound Management. In Q2, the franchises generated $480M, $396M and $318M in sales, respectively.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300208\" data-linked=\"Smith &amp; Nephew up more than 8% on report of Elliott stake\" data-tweet=\"$SNN - Smith &amp; Nephew up more than 8% on report of Elliott stake https://seekingalpha.com/news/3300208-smith-nephew-up-8-on-report-of-elliott-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3300208-smith-nephew-up-8-on-report-of-elliott-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300205\" data-ts=\"1507653708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCI\" target=\"_blank\">JCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300205-johnson-controls-up-nearly-3-call-options-active\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Johnson Controls up nearly 3%, with call options active</a></h4><ul><li>via Bloomberg</li><li>Call option volume in Johnson Controls (NYSE:<a href='https://seekingalpha.com/symbol/JCI' title='Johnson Controls International plc'>JCI</a>) has spiked to more than 15x its 20-day average. Call volume is outpacing put volume by a nearly 15:1 ratio.</li><li>Among the action: The simultaneous purchase of 4K Oct. 43 calls for $0.44, and sale of 2K Oct. $41 calls for $1.03.</li><li>Shares&nbsp;<font color='green'>+2.5%</font>&nbsp;to $41.59</li></ul><div class=\"tiny-share-widget\" data-id=\"3300205\" data-linked=\"Johnson Controls up nearly 3%, with call options active\" data-tweet=\"$JCI - Johnson Controls up nearly 3%, with call options active https://seekingalpha.com/news/3300205-johnson-controls-up-nearly-3-call-options-active?source=tweet\" data-url=\"https://seekingalpha.com/news/3300205-johnson-controls-up-nearly-3-call-options-active\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300199\" data-ts=\"1507652118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RARE\" target=\"_blank\">RARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300199-fda-accepts-burosumab-marketing-application-for-inherited-low-blood-phosphate-action-date\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts burosumab marketing application for inherited low blood phosphate, action date April 17; co-developer Ultragenyx up 1%</a></h4><ul><li>The FDA accepts for review the Biologics License Application &#40;BLA&#41; seeking approval for burosumab to treat pediatric and adult patients with <a href=\"https://www.xlhnetwork.org/what-is-xlh/\" target=\"_blank\">X-linked hypophosphatemia</a> &#40;XLH&#41;, an inherited condition characterized by low levels of phosphate in the blood. The agency's action date under Priority Review status is April 17, 2018.</li><li>Burosumab is a recombinant fully human monoclonal IgG1 antibody that binds to FGF23, a hormone that reduces serum phosphorus and active vitamin D by regulating phosphate excretion and active vitamin D production by the kidney. It was discovered by Kyowa Hakko Kirin and is being co-developed and co-commercialized with Ultragenyx (<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a> <font color='green'>+0.8%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3300199\" data-linked=\"FDA accepts burosumab marketing application for inherited low blood phosphate, action date April 17; co-developer Ultragenyx up 1%\" data-tweet=\"$RARE - FDA accepts burosumab marketing application for inherited low blood phosphate, action date April 17; co-developer Ultragenyx up 1% https://seekingalpha.com/news/3300199-fda-accepts-burosumab-marketing-application-for-inherited-low-blood-phosphate-action-date?source=tweet\" data-url=\"https://seekingalpha.com/news/3300199-fda-accepts-burosumab-marketing-application-for-inherited-low-blood-phosphate-action-date\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300198\" data-ts=\"1507651924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHRW\" target=\"_blank\">CHRW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300198-baml-gives-c-h-robinson-two-notch-upgrade-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML gives C.H. Robinson two-notch upgrade to Buy</a></h4><ul> <li>Bank of America Merrill Lynch upgrades C.H. Robinson (<a href='https://seekingalpha.com/symbol/CHRW' title='C.H. Robinson Worldwide Inc.'>CHRW</a> <font color='green'>+2.2%</font>) in a two-notch lift straight to a Buy rating from Underperform.</li> <li>The investment firm sees considerable upside for the trucking stock due to improved pricing in the sector amid tight capacity.</li> <li>The BAML <a href=\"https://www.marketbeat.com/stocks/NASDAQ/CHRW/\" target=\"_blank\">price target</a> on CHRW is hiked to $86 from $70.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300198\" data-linked=\"BAML gives C.H. Robinson two-notch upgrade to Buy\" data-tweet=\"$CHRW - BAML gives C.H. Robinson two-notch upgrade to Buy https://seekingalpha.com/news/3300198-baml-gives-c-h-robinson-two-notch-upgrade-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3300198-baml-gives-c-h-robinson-two-notch-upgrade-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300195\" data-ts=\"1507651286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300195-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/BORN' title='China New Borun Corporation'>BORN</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300195\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NBEV $BORN $WATT - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3300195-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3300195-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300193\" data-ts=\"1507651007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MVIS\" target=\"_blank\">MVIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300193-microvision-announces-new-board-member\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MicroVision announces new board member</a></h4><ul><li>        MicroVision (NASDAQ:<a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a>) <a href=\"https://seekingalpha.com/pr/16963983-microvision-announces-addition-bernee-d-l-strom-board-directors\" target=\"_blank\">announces</a> the election of Bernee D.L. Strom to its board of directors, which now totals eight members.</li><li>               Strom is the Senior Advisor to investment bank Cascadia Capital and humanitarian aid and disaster relief company SkyLIFE Technologies.&nbsp;</li><li>               MicroVision shares are&nbsp;<font color='green'>up 1.94%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300193\" data-linked=\"MicroVision announces new board member\" data-tweet=\"$MVIS - MicroVision announces new board member https://seekingalpha.com/news/3300193-microvision-announces-new-board-member?source=tweet\" data-url=\"https://seekingalpha.com/news/3300193-microvision-announces-new-board-member\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300192\" data-ts=\"1507650740\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATRS\" target=\"_blank\">ATRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300192-antares-pharma-sells-zomajet-assets-for-up-to-14_5m-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Antares Pharma sells Zomajet assets for up to $14.5M; shares ahead 2%</a></h4><ul><li>Antares Pharma (<a href='https://seekingalpha.com/symbol/ATRS' title='Antares Pharma Inc.'>ATRS</a> <font color='green'>+2.1%</font>) inks a deal with Ferring Pharmaceuticals to sell global rights, including certain fixed assets, to the ZOMAJET needle-free auto injector device for up to $14.5M.</li><li>Under the terms of the <a href=\"https://seekingalpha.com/pr/16963493-antares-pharma-announces-sale-zomajet-needle-free-delivery-system-ferring-pharmaceuticals\" target=\"_blank\">agreement</a>, the purchase price will be paid in four installments: $2.0M upfront, $2.75M subject to conditions, $4.75M contingent on certain closing conditions and $5.0M upon the completion of the transaction.</li><li>The deal should close by the end of 2018.</li><li>Antares has been the global supplier of ZOMAJET to Ferring and JCR Pharmaceutical Company and will continue to be so until the transaction has been completed. The business generated ~$5.5M in annual sales over the past three years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300192\" data-linked=\"Antares Pharma sells Zomajet assets for up to $14.5M; shares ahead 2%\" data-tweet=\"$ATRS - Antares Pharma sells Zomajet assets for up to $14.5M; shares ahead 2% https://seekingalpha.com/news/3300192-antares-pharma-sells-zomajet-assets-for-up-to-14_5m-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3300192-antares-pharma-sells-zomajet-assets-for-up-to-14_5m-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300186\" data-ts=\"1507649018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNC\" target=\"_blank\">GNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300186-gnc-holdings-makes-move-in-india\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GNC Holdings makes a move in India</a></h4><ul> <li>GNC Holdings (<a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='green'>+4.9%</font>) will increase its presence in India through a partnership with franchisee Guardian Healthcare.</li> <li>Guardian aims for availability of GNC products at 4K stores by 2020 in metros and tier 1 towns.</li> <li>\"While the concept of nutraceuticals is at a nascent stage in India, it is heartening to see a significantly heightened intent to include them in daily diet to fulfil nutrition intake. The Indian nutraceuticals market is expected to grow at a compounded annual growth rate of 21per cent and reach $10 billion by 2022 from $4 billion now,\" says GNC India CEO Shadab Khan.</li> <li>Source: <a href=\"http://businesswireindia.com/news/fulldetails/gnc-strengthens-its-presence-india/55304\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3300186\" data-linked=\"GNC Holdings makes a move in India\" data-tweet=\"$GNC - GNC Holdings makes a move in India https://seekingalpha.com/news/3300186-gnc-holdings-makes-move-in-india?source=tweet\" data-url=\"https://seekingalpha.com/news/3300186-gnc-holdings-makes-move-in-india\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300183\" data-ts=\"1507648051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTK\" target=\"_blank\">RTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300183-rentech-to-delist-from-nasdaq-sharesminus-26\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rentech to delist from Nasdaq; shares -26%</a></h4><ul>     <li>Rentech (<a href='https://seekingalpha.com/symbol/RTK' title='Rentech, Inc'>RTK</a> <font color='red'>-26.5%</font>) plunges after the company says it will voluntarily <a href=\"https://seekingalpha.com/pr/16963417-rentech-voluntary-delist-common-shares-nasdaq-shares-trade-otcqb\" target=\"_blank\">delist</a> from the Nasdaq market immediately prior to the market opening on Oct. 16, at which time shares will be listed on the OTCQB Market.</li>     <li>RTK says it was unable to cure its noncompliance with Nasdaq's listing rule that required the company's common shares to trade above $1 for 30 consecutive business days before Oct. 9.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300183\" data-linked=\"Rentech to delist from Nasdaq; shares -26%\" data-tweet=\"$RTK - Rentech to delist from Nasdaq; shares -26% https://seekingalpha.com/news/3300183-rentech-to-delist-from-nasdaq-sharesminus-26?source=tweet\" data-url=\"https://seekingalpha.com/news/3300183-rentech-to-delist-from-nasdaq-sharesminus-26\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300181\" data-ts=\"1507647911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMT\" target=\"_blank\">WMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300181-wal-mart-flies-to-52-week-high-lifts-retail-peers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wal-Mart flies to 52-week high, lifts retail peers</a></h4><ul> <li>Wal-Mart (NYSE:<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a>) is <font color='green'>up 4.35%</font> after the company's aggressive buyback plan and strategic update tantalize investors. Shares hit a 52-week high of $84.48 earlier today.</li> <li>Perhaps the headliner of Wal-Mart's update is the forecast for 40% e-commerce growth for FY19, a pace faster than Amazon's own projections on e-commerce sales.</li> <li>In interesting moves, Target (NYSE:<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a>) is <font color='green'>up 1.99%</font>, Costco (NASDAQ:<a href='https://seekingalpha.com/symbol/COST' title='Costco Wholesale Corporation'>COST</a>) is <font color='green'>1.52% higher</font> and Dollar General (NYSE:<a href='https://seekingalpha.com/symbol/DG' title='Dollar General Corporation'>DG</a>) is showing a&nbsp;<font color='green'>1.78% gain</font>&nbsp;as investors see the Wal-Mart numbers as a positive sign for retail demand over a pure market share grab.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300095-wal-mart-update-includes-new-buybacks-plus-3-percent-growth-forecast\" target=\"_blank\">Wal-Mart update includes new buybacks, +3% growth forecast</a> (Oct. 10)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300181\" data-linked=\"Wal-Mart flies to 52-week high, lifts retail peers\" data-tweet=\"$WMT $WMT $TGT - Wal-Mart flies to 52-week high, lifts retail peers https://seekingalpha.com/news/3300181-wal-mart-flies-to-52-week-high-lifts-retail-peers?source=tweet\" data-url=\"https://seekingalpha.com/news/3300181-wal-mart-flies-to-52-week-high-lifts-retail-peers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300180\" data-ts=\"1507647742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300180-reuters-qualcomm-offers-to-abandon-nxp-patents-to-get-eu-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Qualcomm offers to abandon some NXP patents to get EU approval</a></h4><ul><li>        Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) has offered to give up some patents to get its $38B NXP Semiconductors (NASDAQ:<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a>) acquisition through EU antitrust regulators, according to <a href=\"http://www.reuters.com/article/us-nxp-semicondtrs-m-a-qualcomm-eu/qualcomm-offers-to-buy-nxp-minus-some-patents-to-allay-eu-concerns-sources-idUSKBN1CF20D?feedType=RSS&amp;feedName=businessNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FbusinessNews+%28Business+News%29\" target=\"_blank\">Reuters</a> sources.</li><li>               EU regulators the merged company would incentivize companies to purchase bundled products, which would unfairly push aside rivals, or change NXP&rsquo;s IP licensing.&nbsp;</li><li>               Qualcomm says it will leave the standard essential patents with NXP, which can then sell those patents to another buyer.&nbsp;</li><li>               Qualcomm agreed only to take defensive legal actions against third parties relating to NXP&rsquo;s NFC patents and offered a pledge that rivals could function with NXP products.&nbsp;</li><li>                  The EU Commission will hear comments until the end of the week.&nbsp;&nbsp; </li><li>Qualcomm shares are&nbsp;<font color='green'>up 1.4%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299894-qualcomm-offers-concessions-eu-nxp-deal\" target=\"_blank\">Qualcomm offers concessions to EU in NXP deal</a> (Oct. 9)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300132-qualcomm-declares-0_57-dividend\" target=\"_blank\">Qualcomm declares $0.57 dividend</a> (Oct. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300180\" data-linked=\"Reuters: Qualcomm offers to abandon some NXP patents to get EU approval\" data-tweet=\"$QCOM $QCOM $NXPI - Reuters: Qualcomm offers to abandon some NXP patents to get EU approval https://seekingalpha.com/news/3300180-reuters-qualcomm-offers-to-abandon-nxp-patents-to-get-eu-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3300180-reuters-qualcomm-offers-to-abandon-nxp-patents-to-get-eu-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300156\" data-ts=\"1507647668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300156-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio'>ANAB</a> <font color='green'>+79%</font>. <a href='https://seekingalpha.com/symbol/KALV' title='KalVista Pharmaceticals, Inc.'>KALV</a> <font color='green'>+66%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300156\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$ANAB $KALV $MNKD - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3300156-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3300156-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300174\" data-ts=\"1507647325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRNE\" target=\"_blank\">SRNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300174-sorrento-therapeutics-up-45-in-two-days-news-scarce\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sorrento Therapeutics up 45% in two days but news scarce</a></h4><ul><li>Sorrento Therapeutics (<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a> <font color='green'>+21.4%</font>) is yet another small biotech that has rallied on higher volume. Shares are up ~45% this week on no particular news.</li><li>A key upcoming event is the FDA's decision on its resubmitted marketing application for ZTlido (lidocaine patch 1.8%) for the treatment of postherpetic neuralgia (shingles). The action date is February 28, 2018.</li><li>H.C. Wainwright recently reiterated its Buy rating and $20 (more than a seven-bagger) price target. Oppenheimer also rates it a Buy but with a more modest $7 (169% upside) price target.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294799-fda-accepts-sorrentos-resubmitted-marketing-application-ztlido-action-date-february-28-2018\" target=\"_blank\">FDA accepts Sorrento's resubmitted marketing application for ZTlido, action date February 28, 2018</a> (Sept. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300174\" data-linked=\"Sorrento Therapeutics up 45% in two days but news scarce\" data-tweet=\"$SRNE - Sorrento Therapeutics up 45% in two days but news scarce https://seekingalpha.com/news/3300174-sorrento-therapeutics-up-45-in-two-days-news-scarce?source=tweet\" data-url=\"https://seekingalpha.com/news/3300174-sorrento-therapeutics-up-45-in-two-days-news-scarce\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300173\" data-ts=\"1507646955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVI\" target=\"_blank\">NAVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300173-bloomberg-afl-cio-accuses-navient-of-inside-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: AFL-CIO accuses Navient of inside trading</a></h4><ul><li>        Labor union AFL-CIO asks federal security regulators to investigate Navient (NASDAQ:<a href='https://seekingalpha.com/symbol/NAVI' title='Navient Corp'>NAVI</a>) for insider trading, <a href=\"https://www.bloomberg.com/news/articles/2017-10-10/apple-appeal-on-app-lawsuit-draws-u-s-supreme-court-query\" target=\"_blank\">Bloomberg</a> reports.</li><li>                  The accusation targets trades made before the Labor Day weekend that preceded the public release of a Department of Education letter to a consumer bureau saying the DOE wouldn&rsquo;t provide any more information for policing student loan debt.    </li><li>               AFL-CIO calls out three big purchases of Navient stock the day before the letter went public, which amounted to over 872K shares or about 24% of that day&rsquo;s trading volume.&nbsp;&nbsp;</li><li>        AFL-CIO unions own Navient stock through pension funds. &nbsp;</li><li>Navient shares are&nbsp;<font color='green'>up 1.68%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299575-navient-plunges-subprime-loan-lawsuit-update\" target=\"_blank\">Navient plunges after subprime loan lawsuit (update)</a> (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300173\" data-linked=\"Bloomberg: AFL-CIO accuses Navient of inside trading\" data-tweet=\"$NAVI - Bloomberg: AFL-CIO accuses Navient of inside trading https://seekingalpha.com/news/3300173-bloomberg-afl-cio-accuses-navient-of-inside-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3300173-bloomberg-afl-cio-accuses-navient-of-inside-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300171\" data-ts=\"1507646539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PG\" target=\"_blank\">PG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300171-p-and-g-claims-victory-in-board-vote\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">P&amp;G claims victory in board vote</a></h4><ul> <li>Procter &amp; Gamble (NYSE:<a href='https://seekingalpha.com/symbol/PG' title='The Procter & Gamble Company'>PG</a>) spiked lower after the company reported that Trian has lost its board vote. For its part, Trian is calling the vote <a href=\"https://seekingalpha.com/pr/16964287-trian-says-procter-and-gamble-vote-close-call\" target=\"_blank\">too close</a> to call and wants more time before an official outcome is declared by the independent inspector of elections.</li> <li>Shares of P&amp;G&nbsp;are&nbsp;<font color='red'>down 1.40%</font>&nbsp;after sitting in positive territory just a few minutes ago.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3300171\" data-linked=\"P&amp;G claims victory in board vote\" data-tweet=\"$PG - P&amp;G claims victory in board vote https://seekingalpha.com/news/3300171-p-and-g-claims-victory-in-board-vote?source=tweet\" data-url=\"https://seekingalpha.com/news/3300171-p-and-g-claims-victory-in-board-vote\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300166\" data-ts=\"1507646097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKA\" target=\"_blank\">ROKA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300166-roka-bioscience-up-185-on-potential-combination-a2a-pharma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roka Bioscience up 185% on potential combination with A2A Pharma</a></h4><ul><li>Thinly traded nano cap Roka Bioscience (<a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='green'>+185.2%</font>) rockets on a massive 63x surge in volume in apparent response to the <a href=\"https://www.sec.gov/Archives/edgar/data/1472343/000121390017010406/sc13d1017painter_rokabio.htm\" target=\"_blank\">disclosure </a>of a 340K-share stake by Edward Painter, Founder and CEO of <a href=\"https://www.a2apharma.com/\" target=\"_blank\">A2A Pharmaceuticals</a>, signaling a potential combination with the publicly listed shell.</li><li>Roka announced a deal to sell all of its assets for $17.5M in August.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290157-roka-bio-proceeds-liquidation-agrees-sell-assets-17_5m\" target=\"_blank\">Roka Bio proceeds with liquidation, agrees to sell all assets for $17.5M</a> (Aug. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300166\" data-linked=\"Roka Bioscience up 185% on potential combination with A2A Pharma\" data-tweet=\"$ROKA - Roka Bioscience up 185% on potential combination with A2A Pharma https://seekingalpha.com/news/3300166-roka-bioscience-up-185-on-potential-combination-a2a-pharma?source=tweet\" data-url=\"https://seekingalpha.com/news/3300166-roka-bioscience-up-185-on-potential-combination-a2a-pharma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300164\" data-ts=\"1507645411\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHX\" target=\"_blank\">ATHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300164-sa-contributor-alpha-exposure-bearish-on-athersys-multistem-shares-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SA Contributor Alpha Exposure bearish on Athersys&#39; MultiStem; shares down 9%</a></h4><ul><li>Athersys (<a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a> <font color='red'>-8.7%</font>) is under early pressure on the heels of an <a href=\"https://seekingalpha.com/article/4112631-athersys-zombie-like-multistem-survive-much-longer\" target=\"_blank\">article </a>published by Seeking Alpha Contributor Alpha Exposure who questions the viability of its MultiStem cell therapy.</li><li>The author cites failed clinical trials and the exits of former licensees Pfizer and Chugai as reasons for caution.</li><li><a href=\"http://www.athersys.com/msOverview.cfm\" target=\"_blank\">MultiStem cell therapy</a>&nbsp;is a patented regenerative medicine product that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors produced in response to signals of inflammation and tissue damage.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300164\" data-linked=\"SA Contributor Alpha Exposure bearish on Athersys&#39; MultiStem; shares down 9%\" data-tweet=\"$ATHX - SA Contributor Alpha Exposure bearish on Athersys&#39; MultiStem; shares down 9% https://seekingalpha.com/news/3300164-sa-contributor-alpha-exposure-bearish-on-athersys-multistem-shares-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3300164-sa-contributor-alpha-exposure-bearish-on-athersys-multistem-shares-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300165\" data-ts=\"1507645395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAL\" target=\"_blank\">AAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300165-airlines-show-improved-margins-trend-despite-hurricanes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airlines show improved margins trend despite hurricanes</a></h4><ul> <li>Airline stocks are in rally mode after unit revenue guidance is raised slightly by both American Airlines (<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a> <font color='green'>+4.1%</font>)&nbsp;and United Continental (<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a> <font color='green'>+5.7%</font>).</li> <li>Though both airlines showed a negative impact from the major hurricanes that hit the U.S. and Caribbean, underlying margin improvement can be seen in the quarterly results.</li> <li>Gainers in the sector today include Delta Airlines (<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a> <font color='green'>+2.1%</font>), Spirit Airlines (<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a> <font color='green'>+1.7%</font>), JetBlue (<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a> <font color='green'>+3.3%</font>), Hawaiin Holdings (<a href='https://seekingalpha.com/symbol/HA' title='Hawaiian Holdings, Inc.'>HA</a> <font color='green'>+2%</font>), Southwest Airlines (<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a> <font color='green'>+1.5%</font>), Allegiant Travel (<a href='https://seekingalpha.com/symbol/ALGT' title='Allegiant Travel Company'>ALGT</a> <font color='green'>+2.1%</font>), Volaris (<a href='https://seekingalpha.com/symbol/VLRS' title='Volaris Aviation'>VLRS</a> <font color='green'>+1.9%</font>), Azul (<a href='https://seekingalpha.com/symbol/AZUL' title='Azul'>AZUL</a> <font color='green'>+2%</font>), Copa Holdings (<a href='https://seekingalpha.com/symbol/CPA' title='Copa Holdings, S.A.'>CPA</a> <font color='green'>+2.2%</font>), GOL Linhas (<a href='https://seekingalpha.com/symbol/GOL' title='GOL Linhas Areas Inteligentes S.A.'>GOL</a> <font color='green'>+0.8%</font>) and Alaska Air Group (<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a> <font color='green'>+0.7%</font>).</li><li>Related ETF: <a href='https://seekingalpha.com/symbol/JETS' title='U.S. Global Jets ETF'>JETS</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3300165\" data-linked=\"Airlines show improved margins trend despite hurricanes\" data-tweet=\"$AAL $AAL $UAL - Airlines show improved margins trend despite hurricanes https://seekingalpha.com/news/3300165-airlines-show-improved-margins-trend-despite-hurricanes?source=tweet\" data-url=\"https://seekingalpha.com/news/3300165-airlines-show-improved-margins-trend-despite-hurricanes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300153\" data-ts=\"1507644667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVA\" target=\"_blank\">DVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300153-davita-discloses-potential-450m-exposure-to-operating-income-from-charitable-premium\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DaVita discloses potential $450M exposure to operating income from charitable premium assistance</a></h4><ul><li>Dialysis services provider DaVita (<a href='https://seekingalpha.com/symbol/DVA' title='DaVita HealthCare Partners Inc.'>DVA</a> <font color='green'>+0.2%</font>) issues a <a href=\"https://seekingalpha.com/pr/16963337-davita-provides-disclosures-regarding-charitable-premium-assistance\" target=\"_blank\">statement </a>about its charitable premium assistance activities for some patients.</li><li>Less than 13% (~25K patients) receive support from the American Kidney Fund. Of these, ~1,800 receive charitable premium assistance for individual coverage, including both on-exchange (Obamacare) and off-exchange plans. The loss of individual coverage for these patients could reduce annual operating income of $45M - 90M as previously disclosed.</li><li>About 4K commercially insured patients receive charitable premium support, accounting for ~$450M of the company's expected annual operating income.</li><li>About 80% (~19K patients) are Medicare beneficiaries, many of which would be forced into state Medicaid programs without premium support according to DaVita.</li><li>The company does not believe that charitable premium assistance will be taken away from dialysis patients in need considering its importance to the system and long-standing use, adding that private insurers are not \"unfairly burdened\" by the support.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297134-davita-pressure-sirf-report-patient-co-pay-scheme\" target=\"_blank\">DaVita under pressure on SIRF report on patient co-pay scheme</a> (Sept. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300153\" data-linked=\"DaVita discloses potential $450M exposure to operating income from charitable premium assistance\" data-tweet=\"$DVA - DaVita discloses potential $450M exposure to operating income from charitable premium assistance https://seekingalpha.com/news/3300153-davita-discloses-potential-450m-exposure-to-operating-income-from-charitable-premium?source=tweet\" data-url=\"https://seekingalpha.com/news/3300153-davita-discloses-potential-450m-exposure-to-operating-income-from-charitable-premium\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300160\" data-ts=\"1507644534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300160-western-digital-hits-back-toshibas-chip-unit-plan-b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Digital hits back at Toshiba&#39;s chip unit Plan B</a></h4><ul><li>        Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) releases a new <a href=\"https://www.wdc.com/content/dam/wdc/website/downloadable_assets/eng/investor/10102017_Western_Digital_Q_A.pdf\" target=\"_blank\">FAQ document</a> hitting back at some of the claims surrounding Toshiba&rsquo;s (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a>, <a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) chip unit sale to the Bain-led consortium.</li><li>               The company maintains that it has contractual consent rights to the sale and notes that Bain hasn&rsquo;t reached out to Western Digital as Bain had claimed.&nbsp;</li><li>               Western Digital reiterates that Toshiba doesn&rsquo;t have the right to complete the Fab 6 NAND manufacturing without Western Digital&rsquo;s participation.&nbsp;</li><li>               The company also shoots down Toshiba&rsquo;s contingency plan to set aside the JV interests and sell the rest of its memory unit with a lowered price.&nbsp;</li><li>                  Key quote: &ldquo;Toshiba implies that our arbitration only seeks to prevent the transfer of its equity, in which case they still intend to close even if Toshiba loses. Toshiba ignores that the arbitration seeks to prohibit the transfer of any JV interests without SanDisk&rsquo;s consent. Because Toshiba transferred other JV interests, such as its managerial and control rights in the JVs, Toshiba cannot close its transaction if SanDisk prevails.&rdquo;   </li><li>Western Digital shares are&nbsp;<font color='green'>up 2.29%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299570-deutsche-bank-downgrades-western-digital-toshiba-nand-concerns\" target=\"_blank\">Deutsche Bank downgrades Western Digital on Toshiba, NAND concerns</a> (Oct. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300160\" data-linked=\"Western Digital hits back at Toshiba&#39;s chip unit Plan B\" data-tweet=\"$WDC $WDC $TOSBF - Western Digital hits back at Toshiba&#39;s chip unit Plan B https://seekingalpha.com/news/3300160-western-digital-hits-back-toshibas-chip-unit-plan-b?source=tweet\" data-url=\"https://seekingalpha.com/news/3300160-western-digital-hits-back-toshibas-chip-unit-plan-b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300159\" data-ts=\"1507644316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300159-best-buy-lower-after-cleveland-research-warns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Best Buy lower after Cleveland Research warns</a></h4><ul> <li>Best Buy (NYSE:<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a>) is <font color='red'>down 2.60%</font> in early trading.</li> <li>The retailer was mentioned cautiously by Cleveland Research earlier today, with the boutique firm pointing to the potential impact of iPhone issues affecting sales (h/t <a href=\"https://twitter.com/thenotablecalls/status/917747400206356480\" target=\"_blank\">@NotableCalls</a>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3300159\" data-linked=\"Best Buy lower after Cleveland Research warns\" data-tweet=\"$BBY - Best Buy lower after Cleveland Research warns https://seekingalpha.com/news/3300159-best-buy-lower-after-cleveland-research-warns?source=tweet\" data-url=\"https://seekingalpha.com/news/3300159-best-buy-lower-after-cleveland-research-warns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300155\" data-ts=\"1507643695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNO\" target=\"_blank\">VNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300155-vornado-up-almost-2-after-morgan-stanley-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vornado up almost 2% after Morgan Stanley upgrade</a></h4><ul><li>It's not e-commerce that's hurting NYC retail, says analyst Vikram Malhotra. Instead, he says, it's rents rising too far too fast that have driven higher vacancies.</li><li>Retail sales in NYC are higher by 50% since 2006, but asking rents are up 150% - clearly not sustainable, and the correction in rents (down 15% since a 2015 peak) is about 50% complete.</li><li>Investors, says Malhorta, are too bearish on Vornado (<a href='https://seekingalpha.com/symbol/VNO' title='Vornado Realty Trust'>VNO</a> <font color='green'>+1.8%</font>) as they don't believe the company can retain tenants upon lease expiration, or they're expecting too many store closings. He upgrades to Overweight, with $84 price target. Shares are&nbsp;<font color='green'>up 1.75%&nbsp;</font>to $79.15.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3300155\" data-linked=\"Vornado up almost 2% after Morgan Stanley upgrade\" data-tweet=\"$VNO - Vornado up almost 2% after Morgan Stanley upgrade https://seekingalpha.com/news/3300155-vornado-up-almost-2-after-morgan-stanley-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3300155-vornado-up-almost-2-after-morgan-stanley-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300143\" data-ts=\"1507642134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTNX\" target=\"_blank\">NTNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300143-nutanix-up-after-william-blair-analyst-expects-strong-oct-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutanix up after William Blair analyst expects strong Oct. quarter</a></h4><ul><li>        Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>) shares are&nbsp;<font color='green'>up 4.08%</font>&nbsp;premarket after positive comments from William Blair analyst Jason Ader.</li><li>               Ader says value-added reseller &#40;VAR&#41; checks show Nutanix will have a &ldquo;very strong&rdquo; October quarter featuring large deals.&nbsp;</li><li>                  The analyst expects Nutanix to move towards an all-software model in &ldquo;near future.&rdquo;    </li><li>               Source: <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable Calls </a>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300143\" data-linked=\"Nutanix up after William Blair analyst expects strong Oct. quarter\" data-tweet=\"$NTNX - Nutanix up after William Blair analyst expects strong Oct. quarter https://seekingalpha.com/news/3300143-nutanix-up-after-william-blair-analyst-expects-strong-oct-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3300143-nutanix-up-after-william-blair-analyst-expects-strong-oct-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300142\" data-ts=\"1507642033\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300142-helios-matheson-upplus-700-in-month-who-called\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helios &amp; Matheson up +700% in a month, here&#39;s who called it</a></h4><ul> <li>Helios &amp; Matheson Analytics (NASDAQ:<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>) <font color='green'>soars 14%</font> in premarket trading to follow right on the heels of yesterday's 34% pop.</li> <li>The buying fervor is tied to the company's stake in MoviePass. The movie theater subscription service is catching a huge amount of attention this month.</li> <li>While Maxim started coverage on Helios &amp; Matheson last week with a Buy rating, SA contributor <a href=\"https://seekingalpha.com/article/4107614-moviepass-brilliant-marketing-idea-2017\" target=\"_blank\">Max Verline</a> beat Wall Street to the punch with a recommendation on September 18 when shares were below $3 - a stunning 7X bagger in less than a month.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3300142\" data-linked=\"Helios &amp; Matheson up +700% in a month, here&#39;s who called it\" data-tweet=\"$HMNY - Helios &amp; Matheson up +700% in a month, here&#39;s who called it https://seekingalpha.com/news/3300142-helios-matheson-upplus-700-in-month-who-called?source=tweet\" data-url=\"https://seekingalpha.com/news/3300142-helios-matheson-upplus-700-in-month-who-called\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300138\" data-ts=\"1507641830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIVE\" target=\"_blank\">VIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300138-viveve-medicals-device-for-delivering-geneveve-treatment-okd-in-taiwan-shares-up-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viveve Medical&#39;s device for delivering Geneveve treatment OK&#39;d in Taiwan; shares up 5% premarket</a></h4><ul><li>Thinly traded micro cap Viveve Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/VIVE' title='Viveve Medical, Inc.'>VIVE</a>) is up&nbsp;<font color='green'>5%&nbsp;</font>premarket on modest volume in response to its <a href=\"https://seekingalpha.com/pr/16963750-viveve-announces-regulatory-approval-viveve-system-taiwan\" target=\"_blank\">announcement </a>that its Viveve System has been approved in Taiwan.</li><li>The Viveve System delivers the <a href=\"http://www.viveve.com/geneveve-treatment/\" target=\"_blank\">GENEVEVE treatment</a> for women patients.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300138\" data-linked=\"Viveve Medical&#39;s device for delivering Geneveve treatment OK&#39;d in Taiwan; shares up 5% premarket\" data-tweet=\"$VIVE - Viveve Medical&#39;s device for delivering Geneveve treatment OK&#39;d in Taiwan; shares up 5% premarket https://seekingalpha.com/news/3300138-viveve-medicals-device-for-delivering-geneveve-treatment-okd-in-taiwan-shares-up-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300138-viveve-medicals-device-for-delivering-geneveve-treatment-okd-in-taiwan-shares-up-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300140\" data-ts=\"1507641540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300140-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/KALV' title='KalVista Pharmaceticals, Inc.'>KALV</a> <font color='green'>+137%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300131\" target=\"_blank\">deal</a> with Merck for DME candidate KVD001.</li>     <li><a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio'>ANAB</a> <font color='green'>+47%</font>&nbsp;as its lead candidate ANB020 <a href=\"https://seekingalpha.com/news/3300104\" target=\"_blank\">shows</a> treatment effect in mid-stage dermatitis study.</li>     <li><a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color='green'>+21%</font>&nbsp;as European patent <a href=\"https://seekingalpha.com/news/3300135\" target=\"_blank\">covers</a> Multikine.</li>     <li><a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3300110-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+12%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/VICL' title='Vical Incorporated'>VICL</a> <font color='green'>+11%</font>&nbsp;as it <a href=\"https://seekingalpha.com/news/3300114\" target=\"_blank\">completes</a> the Phase 3 ASP0113 CMV vaccine trial.</li>     <li><a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+7%</font>.</li>     <li>PSDV <font color='green'>+6%&nbsp;</font>on <a href=\"https://seekingalpha.com/news/3300096-psivida-nicox-inks-deal-develop-sustained-release-drug-lower-iop-patients-glaucoma-shares\" target=\"_blank\">deal</a> signed with Nicox.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300140\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$KALV $ANAB $CVM - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3300140-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3300140-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300139\" data-ts=\"1507641505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESRX\" target=\"_blank\">ESRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300139-express-scripts-takes-out-evicore-healthcare-for-3_6b-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Express Scripts takes out eviCore healthcare for $3.6B; shares ahead 2% premarket</a></h4><ul><li>Express Scripts (NASDAQ:<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a>) inks an <a href=\"https://seekingalpha.com/pr/16963905-express-scripts-acquire-evicore-healthcare-accelerates-companys-shift-patient-benefit\" target=\"_blank\">agreement </a>to acquire privately held eviCore healthcare, a leader in evidence-based medical benefit management services, for $3.6B. The transaction should close this quarter.</li><li>Management will provide more details about the deal during its earnings call on October 25.</li><li>Shares are up&nbsp;<font color='green'>2%&nbsp;</font>premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300139\" data-linked=\"Express Scripts takes out eviCore healthcare for $3.6B; shares ahead 2% premarket\" data-tweet=\"$ESRX - Express Scripts takes out eviCore healthcare for $3.6B; shares ahead 2% premarket https://seekingalpha.com/news/3300139-express-scripts-takes-out-evicore-healthcare-for-3_6b-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300139-express-scripts-takes-out-evicore-healthcare-for-3_6b-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300136\" data-ts=\"1507641044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300136-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16963706-izea-reports-q3-bookings-7_9-million\" target=\"_blank\">reporting</a> Q3 total bookings of $7.9M.</li><li><a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a> <font color='red'>-10%</font>.</li><li>CLNT <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3300136\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$IZEA $ATHX $SEII - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3300136-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3300136-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300135\" data-ts=\"1507640927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVM\" target=\"_blank\">CVM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300135-cel-sci-nabs-european-patent-covering-multikine-shares-ahead-24-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CEL-SCI nabs European patent covering Multikine; shares ahead 24% premarket</a></h4><ul><li>Thinly traded nano cap CEL-SCI (NYSEMKT:<a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a>) is up&nbsp;<font color='green'>24%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16963778-cel-sci-granted-european-patent-multikine-s-mechanism-action-making-tumors-visible-immune\" target=\"_blank\">announcement </a>that the European Patent Office has issued Patent # EP 1 879 618 B1 protecting Multikine's mechanism of action to make tumors more visible to the immune system.</li><li>Multikine (Leukocyte Interleukin Injection) is currently in Phase 3 development for head and neck cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300135\" data-linked=\"CEL-SCI nabs European patent covering Multikine; shares ahead 24% premarket\" data-tweet=\"$CVM - CEL-SCI nabs European patent covering Multikine; shares ahead 24% premarket https://seekingalpha.com/news/3300135-cel-sci-nabs-european-patent-covering-multikine-shares-ahead-24-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300135-cel-sci-nabs-european-patent-covering-multikine-shares-ahead-24-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300133\" data-ts=\"1507640545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LVMHF\" target=\"_blank\">LVMHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300133-european-luxury-stocks-stoked-lvmh-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European luxury stocks stoked by LVMH results</a></h4><ul> <li>The luxury apparel sector is waking up after LVMH (<a href='https://seekingalpha.com/symbol/LVMHF' title='LVMH-Moet Hennessy Louis Vuitton'>OTCPK:LVMHF</a>, <a href='https://seekingalpha.com/symbol/LVMUY' title='LVMH-Moet Hennessy Louis Vuitton ADR'>OTCPK:LVMUY</a>) tops estimates with its Q3 report.</li> <li>Organic sales were up 12% for the retailer during the quarter to sail past the 9% growth expected by analysts. Double-digit sales growth was recorded in the selective retailing, watches &amp; jewelry, fashion &amp; leather goods and perfumes &amp; cosmetics categories.</li> <li>Shares of LVMH are <font color='green'>up 2.42%</font> in Paris. Also making gains today in Europe are Christian Dior (<a href='https://seekingalpha.com/symbol/CHDRF' title='Christian Dior S.E.'>OTCPK:CHDRF</a>), Kering (<a href='https://seekingalpha.com/symbol/PPRUF' title='Kering SA'>OTCPK:PPRUF</a>, <a href='https://seekingalpha.com/symbol/PPRUY' title='Kering SA ADR'>OTCPK:PPRUY</a>), Hermes International (<a href='https://seekingalpha.com/symbol/HESAF' title='Hermes International SA'>OTCPK:HESAF</a>, <a href='https://seekingalpha.com/symbol/HESAY' title='Hermes International SA ADR'>OTCPK:HESAY</a>), Pernod Ricard (<a href='https://seekingalpha.com/symbol/PDRDF' title='Pernod Ricard S.A.'>OTCPK:PDRDF</a>, <a href='https://seekingalpha.com/symbol/PDRDY' title='Pernod Ricard S.A. ADR'>OTCPK:PDRDY</a>), Burberry (<a href='https://seekingalpha.com/symbol/BURBY' title='Burberry Group Plc ADR'>OTCPK:BURBY</a>, <a href='https://seekingalpha.com/symbol/BBRYF' title='Burberry Group Plc'>OTCPK:BBRYF</a>), Orchestra Premaman, L'Oreal (<a href='https://seekingalpha.com/symbol/LRLCF' title='L&#39;Oreal Co.'>OTCPK:LRLCF</a>, <a href='https://seekingalpha.com/symbol/LRLCY' title='L&#39;Oreal Co. ADR'>OTCPK:LRLCY</a>), Richemont (<a href='https://seekingalpha.com/symbol/CFRHF' title='Compagnie Financiere Richemont AG'>OTCPK:CFRHF</a>, <a href='https://seekingalpha.com/symbol/CFRUY' title='Compagnie Financiere Richemont AG ADR'>OTCPK:CFRUY</a>) and Remy Cointreau (<a href='https://seekingalpha.com/symbol/REMYF' title='Remy Cointreau SA'>OTCPK:REMYF</a>, <a href='https://seekingalpha.com/symbol/REMYY' title='Remy Cointreau SA ADR'>OTCPK:REMYY</a>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3300133\" data-linked=\"European luxury stocks stoked by LVMH results\" data-tweet=\"$LVMHF $LVMHF $LVMUY - European luxury stocks stoked by LVMH results https://seekingalpha.com/news/3300133-european-luxury-stocks-stoked-lvmh-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3300133-european-luxury-stocks-stoked-lvmh-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300131\" data-ts=\"1507640461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KALV\" target=\"_blank\">KALV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300131-kalvista-pharma-inks-deal-merck-for-dme-candidate-kvd001-shares-up-108-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KalVista Pharma inks deal with Merck for DME candidate KVD001; shares up 108% premarket</a></h4><ul><li>Ultra-thinly traded nano cap KalVista Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KALV' title='KalVista Pharmaceticals, Inc.'>KALV</a>) is up&nbsp;<font color='green'>108%&nbsp;</font>premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16963536-kalvista-pharmaceuticals-announces-collaboration-merck\" target=\"_blank\">announcement </a>of a collaboration agreement with Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) related to lead diabetic macular edema &#40;DME&#41; candidate <a href=\"http://www.kalvista.com/dme.html\" target=\"_blank\">KVD001</a> and future oral DME compounds based on plasma kallikrein inhibition.</li><li>Under the terms of the agreement, KalVista will receive $37M upfront, milestones up to $715M, additional payments if Merck exercises its development options and tiered royalties on net sales.</li><li>Merck has an option to acquire KVD001 for a period following the completion of a Phase 2 proof-of-concept study that will start later this quarter. Merck also has an option to acquire other molecules as part of its ongoing R&amp;D activities.</li><li>KalVista will fund and manage the Phase 2 study of KVD001 and will be responsible for developing additional DME candidates through Phase 2 unless Merck exercises its options earlier.</li><li>Merck has also acquired a 9.9% ownership stake in KalVista via the purchase of 1,070,589 shares of common stock at $8.50 per share.</li><li>KalVista retains full ownership of its oral hereditary angioedema &#40;HAE&#41; <a href=\"http://www.kalvista.com/hae.html\" target=\"_blank\">portfolio</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300131\" data-linked=\"KalVista Pharma inks deal with Merck for DME candidate KVD001; shares up 108% premarket\" data-tweet=\"$KALV $KALV $MRK - KalVista Pharma inks deal with Merck for DME candidate KVD001; shares up 108% premarket https://seekingalpha.com/news/3300131-kalvista-pharma-inks-deal-merck-for-dme-candidate-kvd001-shares-up-108-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300131-kalvista-pharma-inks-deal-merck-for-dme-candidate-kvd001-shares-up-108-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300129\" data-ts=\"1507640406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QLYS\" target=\"_blank\">QLYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300129-morgan-stanley-downgrades-qualys\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley downgrades Qualys</a></h4><ul><li>        Morgan Stanley <a href=\"https://timesofindia.indiatimes.com/business/international-business/ms-upgrades-palo-alto-networks-cuts-qualys-and-symantec/articleshow/61022517.cms\" target=\"_blank\">downgrades</a> Qualys (NASDAQ:<a href='https://seekingalpha.com/symbol/QLYS' title='Qualys'>QLYS</a>) from Equal Weight to Overweight with a $51 price target.</li><li>               Latest analyst ratings for Qualys: 2 Buy, 3 Outperform, and 11 Hold.&nbsp;</li><li>               Median price target: $46.&nbsp;</li><li>               Qualys shares are&nbsp;<font color='red'>down 1.22%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300129\" data-linked=\"Morgan Stanley downgrades Qualys\" data-tweet=\"$QLYS - Morgan Stanley downgrades Qualys https://seekingalpha.com/news/3300129-morgan-stanley-downgrades-qualys?source=tweet\" data-url=\"https://seekingalpha.com/news/3300129-morgan-stanley-downgrades-qualys\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300127\" data-ts=\"1507639847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYMC\" target=\"_blank\">SYMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300127-morgan-stanley-downgrades-symantec\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley downgrades Symantec</a></h4><ul><li>        Morgan Stanley <a href=\"https://timesofindia.indiatimes.com/business/international-business/ms-upgrades-palo-alto-networks-cuts-qualys-and-symantec/articleshow/61022517.cms\" target=\"_blank\">downgrades</a> Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) from Equal Weight to Overweight and cuts the price target by $3 to $34.</li><li>               The firm says Symantec&rsquo;s base case multiple is 18x CY18 EPS, which makes for a modest premium over the market.&nbsp;</li><li>               Symantec shares are&nbsp;<font color='red'>down 1.62%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300127\" data-linked=\"Morgan Stanley downgrades Symantec\" data-tweet=\"$SYMC $NLOK - Morgan Stanley downgrades Symantec https://seekingalpha.com/news/3300127-morgan-stanley-downgrades-symantec?source=tweet\" data-url=\"https://seekingalpha.com/news/3300127-morgan-stanley-downgrades-symantec\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300124\" data-ts=\"1507639428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300124-morgan-stanley-upgrades-palo-alto-networks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley upgrades Palo Alto Networks</a></h4><ul><li>        Morgan Stanley <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Morgan+Stanley+Upgrades+Palo+Alto+Networks+%28PANW%29+to+Overweight/13373250.html\" target=\"_blank\">upgrades</a> Palo Alto Networks (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a>) from Equal Weight to Overweight with a $185 price target, up from $150.</li><li>               Palo Alto Networks shares are&nbsp;<font color='green'>up 2.45%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298228-cybersecurity-moves-top-bank-worry-list-occ\" target=\"_blank\">Cybersecurity moves to top of bank worry list at OCC</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300124\" data-linked=\"Morgan Stanley upgrades Palo Alto Networks\" data-tweet=\"$PANW - Morgan Stanley upgrades Palo Alto Networks https://seekingalpha.com/news/3300124-morgan-stanley-upgrades-palo-alto-networks?source=tweet\" data-url=\"https://seekingalpha.com/news/3300124-morgan-stanley-upgrades-palo-alto-networks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300121\" data-ts=\"1507639138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300121-goldman-sachs-downgrades-jabil\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs downgrades Jabil</a></h4><ul><li>        Goldman Sachs <a href=\"https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+Jabil+Circuit+%28JBL%29+to+Sell/13373426.html\" target=\"_blank\">downgrades</a> Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) from Neutral to Sell and lowers the price target by $2 to $26.</li><li>               Analyst Mark Delaney thinks the company has set expectations too high and is pessimistic on the valuation compared to other companies exposed to Apple.&nbsp;</li><li>Jabil shares are&nbsp;<font color='red'>down 3.66%&nbsp;</font>premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3300121\" data-linked=\"Goldman Sachs downgrades Jabil\" data-tweet=\"$JBL - Goldman Sachs downgrades Jabil https://seekingalpha.com/news/3300121-goldman-sachs-downgrades-jabil?source=tweet\" data-url=\"https://seekingalpha.com/news/3300121-goldman-sachs-downgrades-jabil\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300114\" data-ts=\"1507638846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VICL\" target=\"_blank\">VICL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300114-vical-completes-phase-3-asp0113-cmv-vaccine-trial-shares-up-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vical completes the Phase 3 ASP0113 CMV vaccine trial; shares up 14% premarket</a></h4><ul><li>Vical Incorporated (NASDAQ:<a href='https://seekingalpha.com/symbol/VICL' title='Vical Incorporated'>VICL</a>) <a href=\"https://seekingalpha.com/pr/16963422-vical-announces-completion-phase-3-asp0113-cmv-vaccine-trial\" target=\"_blank\">announces</a> that the last patient completed their final assessment during the one year follow-up period in the multinational Phase 3 registration trial of <a href=\"http://www.vical.com/products/asp0113/default.aspx\" target=\"_blank\">ASP0113</a> in <a href=\"https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation\" target=\"_blank\">hematopoietic cell transplant</a>&nbsp;recipients.</li><li>The enrollment completed in September 2016 with a total of 515 subjects. The primary endpoint of the trial is a composite of overall mortality and <a href=\"https://en.wikipedia.org/wiki/Cytomegalovirus\" target=\"_blank\">cytomegalovirus</a><em>&nbsp;</em>&#40;CMV&#41; end-organ disease, to be assessed one year after transplantation and secondary endpoints include time to first CMV viremia and time to CMV-specific antiviral therapy.</li>   <li>Vical's development partner Astellas&nbsp;Pharma (<a href='https://seekingalpha.com/symbol/ALPMF' title='Astellas Pharma, Inc.'>OTCPK:ALPMF</a>)(<a href='https://seekingalpha.com/symbol/ALPMY' title='Astellas Pharma, Inc. ADR'>OTCPK:ALPMY</a>) conducted the trial and has an exclusive worldwide license from Vical to develop and commercialize ASP0113.&nbsp;Top-line data is expected in Q1 2018.</li><li>Shares of Vical are up&nbsp;<font color='green'>14%</font>&nbsp;premarket on robust volume.</li>          </ul><div class=\"tiny-share-widget\" data-id=\"3300114\" data-linked=\"Vical completes the Phase 3 ASP0113 CMV vaccine trial; shares up 14% premarket\" data-tweet=\"$VICL $BBI $ALPMF - Vical completes the Phase 3 ASP0113 CMV vaccine trial; shares up 14% premarket https://seekingalpha.com/news/3300114-vical-completes-phase-3-asp0113-cmv-vaccine-trial-shares-up-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300114-vical-completes-phase-3-asp0113-cmv-vaccine-trial-shares-up-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300110\" data-ts=\"1507638134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEO\" target=\"_blank\">ABEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300110-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) initiated with Buy rating and $32 (83% upside) price target by Citigroup.</li><li>MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) initiated with Buy rating and $7 (31% upside) price target by H.C. Wainwright. Shares up&nbsp;<font color='green'>11%</font>&nbsp;premarket.</li><li>Strongbridge Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a>) reiterated with Buy rating and $15 (152% upside) price target by Stifel citing bullish prospects for Keveyis and Recorlev.</li><li>AmerisourceBergen (NYSE:<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a>) and McKesson (NYSE:<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a>) upgraded to Outperform by Cowen and Company.</li><li>Quest Diagnostics (NYSE:<a href='https://seekingalpha.com/symbol/DGX' title='Quest Diagnostics Incorporated'>DGX</a>) removed from Conviction List at Goldman Sachs.</li><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) downgraded to Neutral by Credit Suisse after Verzenio flop in lung cancer. Shares down&nbsp;<font color='red'>3%&nbsp;</font>premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300110\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$ABEO $ABEO $MNKD - Premarket analyst action - healthcare https://seekingalpha.com/news/3300110-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3300110-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300104\" data-ts=\"1507637337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANAB\" target=\"_blank\">ANAB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300104-anaptysbios-lead-candidate-anb020-shows-treatment-effect-in-mid-stage-dermatitis-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AnaptysBio&#39;s lead candidate ANB020 shows treatment effect in mid-stage dermatitis study; shares ahead 49% premarket</a></h4><ul><li>Thinly traded AnaptysBio (NASDAQ:<a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio'>ANAB</a>) is up&nbsp;<font color='green'>49%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16963424-anaptysbio-reports-positive-topline-proof-concept-data-phase-2a-clinical-trial-anb020-atopic\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial assessing lead candidate ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis &#40;AD&#41;.</li><li>After a single intravenous dose of ANB020, 75% of patients achieved a 50% improvement in symptoms (EASI-50) from baseline at day 15, 83% achieved EASI-50 at day 29 and 75% achieved EASI-50 at day 57. All 12 patients achieved EASI-50 at one or more timepoints through day 57.</li><li>ANB020 was generally well-tolerated by all subjects. The most frequent adverse events were mild dizziness (n=2) and mild headache (n=2).</li><li>EASI scores will be assessed for each patient up to 140 days post treatment. Compete data will be submitted for presentation at a future medical conference.</li><li>The company plans to initiate a Phase 2b study assessing multiple subcutaneous doses of ANB020 in 200-300 AD patients in H1 2018 with topline results expected in 2019.</li><li><a href=\"https://www.anaptysbio.com/pipeline/anb020/\" target=\"_blank\">ANB020 </a>is an antibody that binds to the pro-inflammatory cytokine interleukin 33 (IL-33), a protein that plays a key role in atopic diseases, including asthma, food allergies and AD.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300104\" data-linked=\"AnaptysBio&#39;s lead candidate ANB020 shows treatment effect in mid-stage dermatitis study; shares ahead 49% premarket\" data-tweet=\"$ANAB - AnaptysBio&#39;s lead candidate ANB020 shows treatment effect in mid-stage dermatitis study; shares ahead 49% premarket https://seekingalpha.com/news/3300104-anaptysbios-lead-candidate-anb020-shows-treatment-effect-in-mid-stage-dermatitis-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3300104-anaptysbios-lead-candidate-anb020-shows-treatment-effect-in-mid-stage-dermatitis-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300096\" data-ts=\"1507636102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYPT\" target=\"_blank\">EYPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300096-psivida-and-nicox-inks-deal-to-develop-sustained-release-drug-to-lower-iop-in-patients\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">pSivida and Nicox inks deal to develop sustained release drug to lower IOP in patients with Glaucoma; shares ahead 12% premarket</a></h4><ul><li>pSivida (PSDV) and Nicox S.A. (<a href='https://seekingalpha.com/symbol/NICXF' title='NICOX SA EUR ORD NEW'>OTCPK:NICXF</a>) <a href=\"https://seekingalpha.com/pr/16963490-psivida-nicox-enter-strategic-collaboration-agreement-develop-sustained-release-drug-lower\" target=\"_blank\">collaborate</a>&nbsp;to explore the potential of combining pSivida's bioerodible sustained release drug delivery system with Nicox's nitric oxide-donating compounds, to develop a sustained release drug to lower intraocular pressure in patients with glaucoma or ocular hypertension.</li>     <li>pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums by Nicox.</li><li>Nicox would make additional payments for any incremental development activities. New intellectual property from the collaboration will be jointly owned.&nbsp; Separate&nbsp;license agreement will be&nbsp;negotiated for any product candidate, developed and commercialize as a result of this collaboration.</li><li>Shares of pSivida are ahead&nbsp;<font color='green'>12%</font>&nbsp;premarket on modest volume.</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3300096\" data-linked=\"pSivida and Nicox inks deal to develop sustained release drug to lower IOP in patients with Glaucoma; shares ahead 12% premarket\" data-tweet=\"$EYPT $EYPT $NICXF - pSivida and Nicox inks deal to develop sustained release drug to lower IOP in patients with Glaucoma; shares ahead 12% premarket https://seekingalpha.com/news/3300096-psivida-and-nicox-inks-deal-to-develop-sustained-release-drug-to-lower-iop-in-patients?source=tweet\" data-url=\"https://seekingalpha.com/news/3300096-psivida-and-nicox-inks-deal-to-develop-sustained-release-drug-to-lower-iop-in-patients\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300099\" data-ts=\"1507636090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIG\" target=\"_blank\">AIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300099-aig-down-2-after-estimating-3b-in-catastrophe-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AIG down 2% after estimating $3B in catastrophe losses</a></h4><ul><li>A pretax loss of $2.9B-$3.1B from this quarter's hurricanes and earthquakes is higher than the $2.5B estimated by Morgan Stanley.</li><li>The team there remains bullish, however, <a href=\"http://www.reuters.com/article/us-aig-outlook/aig-sees-third-quarter-catastrophe-losses-of-about-3-billion-idUSKBN1CE2EP?utm_source=Twitter&amp;utm_medium=Social\" target=\"_blank\">noting the loss amounts</a> to just 2.6% of book value. The insurer also has more than $3.5B in cash and short-term investments on its books.</li><li><a href='https://seekingalpha.com/symbol/AIG' title='American International Group Inc'>AIG</a> is&nbsp;<font color='red'>lower by 2.1%</font>&nbsp;in premarket action.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3300043-aig-cat-losses-3b-q3\" target=\"_blank\">AIG cat losses to be about $3B in Q3</a> (Oct. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300099\" data-linked=\"AIG down 2% after estimating $3B in catastrophe losses\" data-tweet=\"$AIG - AIG down 2% after estimating $3B in catastrophe losses https://seekingalpha.com/news/3300099-aig-down-2-after-estimating-3b-in-catastrophe-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3300099-aig-down-2-after-estimating-3b-in-catastrophe-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300098\" data-ts=\"1507636047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KALV\" target=\"_blank\">KALV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300098-kalvista-pharma-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KalVista Pharma trading halted pending news</a></h4><ul><li>Nasdaq has <a href=\"http://www.nasdaqtrader.com/trader.aspx?id=tradehalts\" target=\"_blank\">suspended trading </a>in KalVista Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KALV' title='KalVista Pharmaceticals, Inc.'>KALV</a>) pending the release of news. Trading will resume at 8:00 am ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300098\" data-linked=\"KalVista Pharma trading halted pending news\" data-tweet=\"$KALV - KalVista Pharma trading halted pending news https://seekingalpha.com/news/3300098-kalvista-pharma-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3300098-kalvista-pharma-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300091\" data-ts=\"1507635064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300091-lillys-breast-cancer-med-abemaciclib-flunks-late-stage-lung-cancer-study-shares-slip-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilly&#39;s breast cancer med abemaciclib flunks late-stage lung cancer study; shares slip 2% premarket</a></h4><ul><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) is off&nbsp;<font color='red'>2%&nbsp;</font>premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16963443-lilly-reports-topline-results-phase-3-juniper-trial-evaluating-verzenio-abemaciclib-kras\" target=\"_blank\">announcement </a>of a negative outcome from its Phase 3 JUNIPER study evaluating Verzenio (abemaciclib) for the treatment of KRAS-positive advanced non-small cell lung cancer &#40;NSCLC&#41;. The study failed to achieve the primary endpoint of overall survival &#40;OS&#41; due, at least in part, to the control arm showing a higher-than-expected OS. Secondary endpoints of progression-free survival &#40;PFS&#41; and overall response rate &#40;ORR&#41; demonstrated evidence of monotherapy activity.</li><li>The results will be submitted for presentation at a medical meeting next year.</li><li>Abemaciclib is a cell cycle inhibitor that is designed to block the growth of cancer cells by inhibiting the enzymes&nbsp;<a href=\"https://en.wikipedia.org/wiki/Cyclin-dependent_kinase_4\" target=\"_blank\">CDK4&nbsp;</a>and&nbsp;<a href=\"https://en.wikipedia.org/wiki/Cyclin-dependent_kinase_6\" target=\"_blank\">CDK6</a>. The FDA approved it in September for the treatment of HR+/HER2- breast cancer when combined with AstraZeneca's Faslodex (fulvestrant).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298266-fda-oks-lillys-breast-cancer-drug-abemaciclib-shares-1-percent\" target=\"_blank\">FDA OKs Lilly's breast cancer drug abemaciclib; shares up 1%</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3300091\" data-linked=\"Lilly&#39;s breast cancer med abemaciclib flunks late-stage lung cancer study; shares slip 2% premarket\" data-tweet=\"$LLY - Lilly&#39;s breast cancer med abemaciclib flunks late-stage lung cancer study; shares slip 2% premarket https://seekingalpha.com/news/3300091-lillys-breast-cancer-med-abemaciclib-flunks-late-stage-lung-cancer-study-shares-slip-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3300091-lillys-breast-cancer-med-abemaciclib-flunks-late-stage-lung-cancer-study-shares-slip-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3300087\" data-ts=\"1507634028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3300087-pfizer-mulling-potential-sale-of-consumer-healthcare-unit-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pfizer mulling potential sale of consumer healthcare unit; shares up 1% premarket</a></h4><ul><li>Citing its continuing efforts to allocate its resources and capital to best serve patients and shareholders, Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) is <a href=\"https://seekingalpha.com/pr/16963442-pfizer-reviewing-strategic-alternatives-consumer-healthcare-business\" target=\"_blank\">exploring strategic alternati</a>ves for its Consumer Healthcare business which generated ~$3.4B in sales in 2016.</li><li>The unit boasts ten brands that produce greater than $100M in annual sales, including Centrum and Advil. Major product categories include dietary supplements, pain medications, gastrointestinal, respiratory and personal care.</li><li>The company it is considering a full or partial separation through a spinoff, sale or other transaction.</li><li>Centerview Partners LLC, Guggenheim Securities LLC and Morgan Stanley &amp; Co. LLC are advising.</li><li>Shares are up&nbsp;<font color='green'>1%&nbsp;</font>premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3300087\" data-linked=\"Pfizer mulling potential sale of consumer healthcare unit; shares up 1% premarket\" data-tweet=\"$PFE - Pfizer mulling potential sale of consumer healthcare unit; shares up 1% premarket https://seekingalpha.com/news/3300087-pfizer-mulling-potential-sale-of-consumer-healthcare-unit-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3300087-pfizer-mulling-potential-sale-of-consumer-healthcare-unit-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":66,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}